Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma

We present our initial experience in using single modality fluoromisonidazole (FMISO) PET/MR imaging to noninvasively evaluate the biological effects induced by bevacizumab therapy in a patient treated for recurrent high grade glioma. In this index patient, bevacizumab therapy resulted in the develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Barajas, Ramon F., Pampaloni, Miguel H., Clarke, Jennifer L., Seo, Youngho, Savic, Dragana, Hawkins, Randall A., Behr, Spencer C., Chang, Susan M., Berger, Mitchel, Dillon, William P., Cha, Soonmee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352456/
https://www.ncbi.nlm.nih.gov/pubmed/25793136
http://dx.doi.org/10.1155/2015/731361
Descripción
Sumario:We present our initial experience in using single modality fluoromisonidazole (FMISO) PET/MR imaging to noninvasively evaluate the biological effects induced by bevacizumab therapy in a patient treated for recurrent high grade glioma. In this index patient, bevacizumab therapy resulted in the development of nonenhancing tumor characterized by reduced diffusion and markedly decreased FMISO uptake in the setting of maintained CBF and CBV. These observations suggest that the dynamic biological interplay between tissue hypoxia and vascular normalization occurring within treated recurrent high grade glioma can be captured utilizing FMISO PET/MR imaging.

Ejemplares similares